Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
ConclusionTo the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Eating Disorders & Weight Management | Endocrine Therapy | Estradiol | Laboratory Medicine | Neoadjuvant Therapy | Obesity | Study | Women